What’s Next for Peptide Regulation: The Compounds FDA Reviews Before February
Quick answer: In July 2026, an FDA advisory committee recommended six peptides - BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon - for the 503A Bulks List. Those votes were advisory, not binding, and nothing is authorized today. The more consequential news is what comes next: FDA has signaled it will review a second group, including […]
